The loss of MHC-II expression in DLBCL has been associated with genetic alterations, including the overexpression or gain-of-function mutations in polycomb proteins such as EZH2 (49), the enzymatic subunit within PRC2. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.